Jeil Pharmaceutical Co., Ltd. (KOSPI: 271980.KS, “Jeil Pharm / 제일약품”) is a specialty and generic pharmaceutical company headquartered in Seoul, South Korea, founded in 1959. The company’s core business centers on the discovery and development of pharmaceutical products, followed by manufacturing and supply to wholesalers and healthcare providers in South ...Jeil Pharmaceutical Co., Ltd. (KOSPI: 271980.KS, “Jeil Pharm / 제일약품”) is a specialty and generic pharmaceutical company headquartered in Seoul, South Korea, founded in 1959. The company’s core business centers on the discovery and development of pharmaceutical products, followed by manufacturing and supply to wholesalers and healthcare providers in South Korea, with additional reach through exports to roughly 40 countries across regions such as ASEAN, Central and South America, and Africa.
From a product and therapeutic perspective, Jeil covers a broad portfolio of medicine categories. The company’s offerings span antibiotics, gastrointestinal health, cardiovascular treatments, neuropsychiatric disorders, oncology (cancer-related medicines), endocrine-related conditions, urological products, viral infection treatments, and antihistamine remedies. This multi-therapeutic approach typically requires disciplined development planning, regulatory management, and manufacturing capabilities, since each class of drug can carry distinct formulation, quality-control, and stability requirements.
Jeil also emphasizes R&D and pharmaceutical technology. Public company descriptions indicate the presence of central R&D capabilities and a pharmaceutical technology research institute, as well as an active drug pipeline and clinical development activities. In operational terms, pharma cost structures generally include R&D (drug development and clinical programs), raw-material and API procurement, manufacturing overhead (quality systems, clean/controlled production environments), packaging, regulatory compliance, and pharmacovigilance. While specific BOM details are not provided in the reference data, Jeil’s manufacturing nature implies that bill-of-materials and cost drivers likely include pharmaceutical ingredients, formulation excipients, packaging components (e.g., blister/box systems), and quality assurance testing.
Financially, the supplied ttm snapshot shows a market valuation (market cap) of about KRW 148.5B and enterprise value (EV) of about KRW 202.3B. Profitability indicators in the ttm data suggest relatively modest margins (e.g., net profit margin around 1.7% and operating profit margin around 0.5%), alongside investment activity reflected in capex-related ratios. The company’s balance-sheet and liquidity metrics indicate a current ratio above 1 (current ratio ~1.33) but also a solvency ratio that appears relatively low in the provided dataset; these patterns are consistent with businesses that carry working-capital needs (inventory and receivables) typical in pharmaceuticals.
In terms of corporate leadership, the provided data lists Seok-Jae Sung as CEO. The company employs a mid-sized workforce for the sector; the supplied sources cite 973 employees and a company-size range of 501–1,000, aligning with its manufacturing and R&D scale.
Looking ahead, Jeil’s stated strategic direction (as reflected in public descriptions) includes improving capabilities as an injection/medication manufacturer in a global era and increasing development of higher-value products. For stakeholders, the main watchpoints typically include pipeline progress (new launches and approvals), the ability to sustain or expand export markets, maintaining quality and regulatory compliance across jurisdictions, and improving profitability through product mix, manufacturing efficiency, and effective commercialization.
